(Q44960162)

7 December 2017

Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease (English)

1 reference

chronic obstructive pulmonary disease

7 December 2017

0 references

0 references

author name string

Don D Sin

1

1 reference

7 December 2017

Paige Lacy

2

1 reference

7 December 2017

Ernest York

3

1 reference

7 December 2017

S F Paul Man

4

1 reference

7 December 2017

language of work or name

English

0 references

publication date

30 June 2004

1 reference

American Journal of Respiratory and Critical Care Medicine

7 December 2017

1 reference

7 December 2017

170

1 reference

7 December 2017

760-765

1 reference

7 December 2017

7

1 reference

Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary

7 December 2017

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200404-543OC

Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200404-543OC

Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200404-543OC

Impaired lung function and mortality risk in men and women: findings from the Renfrew and Paisley prospective population study

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200404-543OC

Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200404-543OC

Symptoms of chronic bronchitis and the risk of coronary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200404-543OC

Hospitalizations and mortality in the Lung Health Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200404-543OC

Atherosclerosis — An Inflammatory Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200404-543OC

Clinical application of C-reactive protein for cardiovascular disease detection and prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200404-543OC

Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200404-543OC

Immunosuppressive Therapy for the Prevention of Restenosis after Coronary Artery Stent Implantation (IMPRESS Study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200404-543OC

The effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease: a double-blind, placebo-controlled biopsy study

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200404-543OC

Inhaled corticosteroids reduce neutrophilic bronchial inflammation in patients with chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200404-543OC

Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200404-543OC

Interrelationships among circulating interleukin-6, C-reactive protein, and traditional cardiovascular risk factors in women

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200404-543OC

Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200404-543OC

Chronic obstructive pulmonary disease: molecular and cellularmechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200404-543OC

Association between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200404-543OC

Chronic obstructive pulmonary disease. 5: systemic effects of COPD

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200404-543OC

New Markers of Inflammation and Endothelial Cell Activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200404-543OC

A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200404-543OC

Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200404-543OC

Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200404-543OC

C-reactive protein: a critical update

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200404-543OC

Airway epithelial inflammatory responses and clinical parameters in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200404-543OC

Comparison of pharmacokinetics and systemic effects of inhaled fluticasone propionate in patients with asthma and healthy volunteers: a randomised crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200404-543OC

Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200404-543OC

Systemic anti-inflammatory mediators in COPD: increase in soluble interleukin 1 receptor II during treatment of exacerbations

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200404-543OC

Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200404-543OC

Contemporary management of chronic obstructive pulmonary disease: scientific review

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200404-543OC

10.1164/RCCM.200404-543OC

21 January 2018

Identifiers

DOI

1 reference

7 December 2017

1 reference